Listed

Actuate Therapeutics, Inc.

ACTUNasdaqCIK 1652935HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.9m, Q2 FY2026
Net income−$4.9m, Q2 FY2026
Actuate Therapeutics, Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k5,762Research and development, period not labelled, three months to 2023-09-30$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure6,646Research and development, period not labelled, three months to 2023-12-31$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001683168-25-001581. Derived: 12-month figure less the 9-month figure.Report this figure6,860Research and development, period not labelled, three months to 2024-03-31$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure4,373Research and development, Q2 FY2024, three months to 2024-06-30$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure3,757Research and development, Q3 FY2024, three months to 2024-09-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure3,686Research and development, Q4 FY2024, three months to 2024-12-31$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure3,220Research and development, Q1 FY2025, three months to 2025-03-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure2,765Research and development, Q2 FY2025, three months to 2025-06-30$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure2,178Research and development, Q3 FY2025, three months to 2025-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure2,130Research and development, Q4 FY2025, three months to 2025-12-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure2,565Research and development, Q1 FY2026, three months to 2026-03-31$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure2,067Research and development, Q2 FY2026, three months to 2026-06-30$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Operating income$k(6,476)Operating income, period not labelled, three months to 2023-09-30−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure(7,615)Operating income, period not labelled, three months to 2023-12-31−$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001683168-25-001581. Derived: 12-month figure less the 9-month figure.Report this figure(7,773)Operating income, period not labelled, three months to 2024-03-31−$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure(5,435)Operating income, Q2 FY2024, three months to 2024-06-30−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure(5,393)Operating income, Q3 FY2024, three months to 2024-09-30−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(6,559)Operating income, Q4 FY2024, three months to 2024-12-31−$6.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(6,366)Operating income, Q1 FY2025, three months to 2025-03-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(5,969)Operating income, Q2 FY2025, three months to 2025-06-30−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(5,472)Operating income, Q3 FY2025, three months to 2025-09-30−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(4,688)Operating income, Q4 FY2025, three months to 2025-12-31−$4.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(5,706)Operating income, Q1 FY2026, three months to 2026-03-31−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(4,907)Operating income, Q2 FY2026, three months to 2026-06-30−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Interest expense$k5.1Interest expense, period not labelled, three months to 2023-09-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure5.1Interest expense, period not labelled, three months to 2023-12-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-13, accession 0001683168-25-001581. Derived: 12-month figure less the 9-month figure.Report this figure5.1Interest expense, period not labelled, three months to 2024-03-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure5.1Interest expense, Q2 FY2024, three months to 2024-06-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure3.5Interest expense, Q3 FY2024, three months to 2024-09-30$3.5k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure5.1Interest expense, Q4 FY2024, three months to 2024-12-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure5.1Interest expense, Q1 FY2025, three months to 2025-03-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure5.1Interest expense, Q2 FY2025, three months to 2025-06-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure5.1Interest expense, Q3 FY2025, three months to 2025-09-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure5.1Interest expense, Q4 FY2025, three months to 2025-12-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure5.1Interest expense, Q1 FY2026, three months to 2026-03-31$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure5.1Interest expense, Q2 FY2026, three months to 2026-06-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Net income$k(6,338)Net income, period not labelled, three months to 2023-09-30−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure(7,612)Net income, period not labelled, three months to 2023-12-31−$7.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001683168-25-001581. Derived: 12-month figure less the 9-month figure.Report this figure(8,296)Net income, period not labelled, three months to 2024-03-31−$8.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(6,572)Net income, Q2 FY2024, three months to 2024-06-30−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(5,971)Net income, Q3 FY2024, three months to 2024-09-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(6,446)Net income, Q4 FY2024, three months to 2024-12-31−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(6,317)Net income, Q1 FY2025, three months to 2025-03-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(5,949)Net income, Q2 FY2025, three months to 2025-06-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(5,407)Net income, Q3 FY2025, three months to 2025-09-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(4,554)Net income, Q4 FY2025, three months to 2025-12-31−$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(5,626)Net income, Q1 FY2026, three months to 2026-03-31−$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(4,867)Net income, Q2 FY2026, three months to 2026-06-30−$4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Diluted EPS$ per share(4.31)Diluted EPS, period not labelled, three months to 2023-09-30−$4.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figurenot reported(5.40)Diluted EPS, period not labelled, three months to 2024-03-31−$5.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure(4.20)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$4.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure(0.55)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figurenot reported(0.32)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(0.30)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(0.25)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figurenot reported(0.24)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(0.20)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Basic EPS$ per share(4.31)Basic EPS, period not labelled, three months to 2023-09-30−$4.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figurenot reported(5.40)Basic EPS, period not labelled, three months to 2024-03-31−$5.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure(4.20)Basic EPS, Q2 FY2024, three months to 2024-06-30−$4.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure(0.55)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figurenot reported(0.32)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(0.30)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(0.25)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figurenot reported(0.24)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(0.20)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure

Balance sheet

Cash and equivalents$4.4m, Q2 FY2026
Shareholders' equity$989.2k, Q2 FY2026
Actuate Therapeutics, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reportednot reportednot reported0.4Cash and equivalents, Q2 FY2024, at 2024-06-30$351.7k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure13.5Cash and equivalents, Q3 FY2024, at 2024-09-30$13.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure8.6Cash and equivalents, FY2024, at 2024-12-31$8.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-13, accession 0001683168-25-001581.Report this figure3.9Cash and equivalents, Q1 FY2025, at 2025-03-31$3.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure6.5Cash and equivalents, Q2 FY2025, at 2025-06-30$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure16.9Cash and equivalents, Q3 FY2025, at 2025-09-30$16.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure13.2Cash and equivalents, FY2025, at 2025-12-31$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure8.1Cash and equivalents, Q1 FY2026, at 2026-03-31$8.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure4.4Cash and equivalents, Q2 FY2026, at 2026-06-30$4.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Current assets$mnot reported3.0Current assets, period not labelled, at 2023-12-31$3.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001683168-25-001581.Report this figurenot reported0.5Current assets, Q2 FY2024, at 2024-06-30$549.7k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure14.3Current assets, Q3 FY2024, at 2024-09-30$14.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure9.2Current assets, FY2024, at 2024-12-31$9.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure4.2Current assets, Q1 FY2025, at 2025-03-31$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure6.7Current assets, Q2 FY2025, at 2025-06-30$6.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure17.4Current assets, Q3 FY2025, at 2025-09-30$17.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure13.6Current assets, FY2025, at 2025-12-31$13.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure8.5Current assets, Q1 FY2026, at 2026-03-31$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure4.7Current assets, Q2 FY2026, at 2026-06-30$4.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Total assets$mnot reported3.0Total assets, period not labelled, at 2023-12-31$3.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001683168-25-001581.Report this figurenot reported1.7Total assets, Q2 FY2024, at 2024-06-30$1.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure14.3Total assets, Q3 FY2024, at 2024-09-30$14.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure9.3Total assets, FY2024, at 2024-12-31$9.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure4.5Total assets, Q1 FY2025, at 2025-03-31$4.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure7.0Total assets, Q2 FY2025, at 2025-06-30$7.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure17.7Total assets, Q3 FY2025, at 2025-09-30$17.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure14.0Total assets, FY2025, at 2025-12-31$14.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure8.9Total assets, Q1 FY2026, at 2026-03-31$8.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure5.2Total assets, Q2 FY2026, at 2026-06-30$5.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Current liabilities$mnot reported6.9Current liabilities, period not labelled, at 2023-12-31$6.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001683168-25-001581.Report this figurenot reported20.1Current liabilities, Q2 FY2024, at 2024-06-30$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure8.5Current liabilities, Q3 FY2024, at 2024-09-30$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure8.8Current liabilities, FY2024, at 2024-12-31$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure9.2Current liabilities, Q1 FY2025, at 2025-03-31$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure9.2Current liabilities, Q2 FY2025, at 2025-06-30$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure6.4Current liabilities, Q3 FY2025, at 2025-09-30$6.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure5.7Current liabilities, FY2025, at 2025-12-31$5.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure4.7Current liabilities, Q1 FY2026, at 2026-03-31$4.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure3.8Current liabilities, Q2 FY2026, at 2026-06-30$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Total liabilities$mnot reported8.4Total liabilities, period not labelled, at 2023-12-31$8.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001683168-25-001581.Report this figurenot reported21.8Total liabilities, Q2 FY2024, at 2024-06-30$21.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure8.9Total liabilities, Q3 FY2024, at 2024-09-30$8.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure9.2Total liabilities, FY2024, at 2024-12-31$9.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure9.6Total liabilities, Q1 FY2025, at 2025-03-31$9.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure9.6Total liabilities, Q2 FY2025, at 2025-06-30$9.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure6.8Total liabilities, Q3 FY2025, at 2025-09-30$6.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure6.1Total liabilities, FY2025, at 2025-12-31$6.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure5.1Total liabilities, Q1 FY2026, at 2026-03-31$5.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure4.2Total liabilities, Q2 FY2026, at 2026-06-30$4.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure
Shareholders' equity$m(92.1)Shareholders' equity, period not labelled, at 2023-09-30−$92.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure(99.6)Shareholders' equity, period not labelled, at 2023-12-31−$99.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001683168-26-002257.Report this figure(108)Shareholders' equity, period not labelled, at 2024-03-31−$107.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure(114)Shareholders' equity, Q2 FY2024, at 2024-06-30−$114.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure5.4Shareholders' equity, Q3 FY2024, at 2024-09-30$5.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure0.1Shareholders' equity, FY2024, at 2024-12-31$104.2k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(5.1)Shareholders' equity, Q1 FY2025, at 2025-03-31−$5.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure(2.7)Shareholders' equity, Q2 FY2025, at 2025-06-30−$2.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure10.9Shareholders' equity, Q3 FY2025, at 2025-09-30$10.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure7.9Shareholders' equity, FY2025, at 2025-12-31$7.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure3.8Shareholders' equity, Q1 FY2026, at 2026-03-31$3.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure1.0Shareholders' equity, Q2 FY2026, at 2026-06-30$989.2k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure

Cash flow

Operating cash flow−$4.4m, Q2 FY2026
Actuate Therapeutics, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(5,638)Operating cash flow, period not labelled, three months to 2023-09-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001683168-24-007971. Derived: 9-month figure less the 6-month figure.Report this figure(5,512)Operating cash flow, period not labelled, three months to 2023-12-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001683168-25-001581. Derived: 12-month figure less the 9-month figure.Report this figure(5,248)Operating cash flow, period not labelled, three months to 2024-03-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure(2,674)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001683168-25-006159. Derived: 6-month figure less the 3-month figure.Report this figure(9,149)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001683168-25-008323. Derived: 9-month figure less the 6-month figure.Report this figure(4,772)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(4,619)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(4,174)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001683168-26-006472. Derived: 6-month figure less the 3-month figure.Report this figure(6,678)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001683168-25-008323. Derived: 9-month figure less the 6-month figure.Report this figure(3,736)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001683168-26-002257. Derived: 12-month figure less the 9-month figure.Report this figure(5,017)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure(4,405)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001683168-26-006472. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)23.87m, Q2 FY2026
Actuate Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2023-06-30period not labelled2023-09-30period not labelled2024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares1.4Diluted shares (weighted), period not labelled, three months to 2023-06-301,422,164 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-09-24, accession 0001683168-24-006623.Report this figure1.5Diluted shares (weighted), period not labelled, three months to 2023-09-301,472,182 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001683168-24-007971.Report this figure1.5Diluted shares (weighted), period not labelled, three months to 2024-03-311,535,167 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001683168-25-003705.Report this figure1.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,565,777 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001683168-25-006159.Report this figure10.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3010,772,640 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure19.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3119,497,731 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure19.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3019,646,475 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure21.4Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3021,394,965 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001683168-25-008323.Report this figure23.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3123,537,134 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001683168-26-003909.Report this figure23.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3023,871,850 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure

Shares outstanding: 24.01mShares outstanding, period not labelled, at 2026-08-1324,014,202 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001683168-26-006472.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.